Literature DB >> 1934864

Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities.

W Kalow1, B K Tang.   

Abstract

Caffeine was used as a metabolic probe to screen healthy subjects for their activities of two enzymes, deduced to be CYP1A2 (an inducible cytochrome P450) and xanthine oxidase. A longitudinal study revealed modest effects of caffeine dose, ethanol intake, and time-of-day on the CYP1A2 index, without any effect on the xanthine oxidase index. The coefficients of intraindividual variation not accounted for were 5.0% for the xanthine oxidase and 17.2% for the CYP1A2 index. In a population study, both indexes showed a log normal distribution, with CYP1A2 values of most subjects covering a 6.3-fold range but only a 1.7-fold range with xanthine oxidase. The CYP1A2 index was 33% decreased in women who used oral contraceptives and substantially increased in cigarette smokers. Neither the CYP1A2 nor the xanthine oxidase index differed between volunteers of Chinese and European extraction. Four of 178 subjects showed unexplained low xanthine oxidase values (i.e., values several standard deviations below the mean).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1934864     DOI: 10.1038/clpt.1991.176

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  62 in total

Review 1.  Effects of obesity on pharmacokinetics implications for drug therapy.

Authors:  G Cheymol
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

Review 2.  Genetics of caffeine consumption and responses to caffeine.

Authors:  Amy Yang; Abraham A Palmer; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2010-06-09       Impact factor: 4.530

3.  Determination of -3858G-->A and -164C-->A genetic polymorphisms of CYP1A2 in blood and saliva by rapid allelic discrimination: large difference in the prevalence of the -3858G-->A mutation between Caucasians and Asians.

Authors:  Liliane Todesco; Michael Török; Stephan Krähenbühl; Markus Wenk
Journal:  Eur J Clin Pharmacol       Date:  2003-07-08       Impact factor: 2.953

Review 4.  The clinical pharmacology of 6-mercaptopurine.

Authors:  L Lennard
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 5.  Pharmacogenetics and psychiatry.

Authors:  Amlan Basu; Eva Tsapakis; Kathy Aitchison
Journal:  Curr Psychiatry Rep       Date:  2004-04       Impact factor: 5.285

6.  Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity.

Authors:  Sebastian Härtter; Anna Nordmark; Dirk-Matthias Rose; Leif Bertilsson; Gunnel Tybring; Kari Laine
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

7.  Tacrine is not an ideal probe drug for measuring CYP1A2 activity in vivo.

Authors:  J T Larsen; L L Hansen; K Brosen
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

8.  Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism.

Authors:  Christoph Sachse; Upinder Bhambra; Gillian Smith; Tracy J Lightfoot; Jennifer H Barrett; Jenna Scollay; R Colin Garner; Alan R Boobis; C Roland Wolf; Nigel J Gooderham
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

9.  Induction of P-450 in workers exposed to dioxin.

Authors:  W Halperin; W Kalow; M H Sweeney; B K Tang; M Fingerhut; B Timpkins; K Wille
Journal:  Occup Environ Med       Date:  1995-02       Impact factor: 4.402

10.  Caffeine as a metabolic probe: a comparison of the metabolic ratios used to assess CYP1A2 activity.

Authors:  L J Notarianni; S E Oliver; P Dobrocky; P N Bennett; B W Silverman
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.